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Abstract
Background: Aberrant expression of HGF/SF and its receptor, c-Met, often correlates with advanced prostate
cancer. Our previous study showed that expression of c-Met in prostate cancer cells was increased after
attenuation of androgen receptor (AR) signalling. This suggested that current androgen ablation therapy for
prostate cancer activates c-Met expression and may contribute to development of more aggressive, castration
resistant prostate cancer (CRPC). Therefore, we directly assessed the efficacy of c-Met inhibition during androgen
ablation on the growth and progression of prostate cancer.
Methods: We tested two c-Met small molecule inhibitors, PHA-665752 and PF-2341066, for anti-proliferative activity
by MTS assay and cell proliferation assay on human prostate cancer cell lines with different levels of androgen
sensitivity. We also used renal subcapsular and castrated orthotopic xenograft mouse models to assess the effect of
the inhibitors on prostate tumor formation and progression.
Results: We demonstrated a dose-dependent inhibitory effect of PHA-665752 and PF-2341066 on the proliferation
of human prostate cancer cells and the phosphorylation of c-Met. The effect on cell proliferation was stronger in
androgen insensitive cells. The c-Met inhibitor, PF-2341066, significantly reduced growth of prostate tumor cells in
the renal subcapsular mouse model and the castrated orthotopic mouse model. The effect on cell proliferation was
greater following castration.
Conclusions: The c-Met inhibitors demonstrated anti-proliferative efficacy when combined with androgen ablation
therapy for advanced prostate cancer.
Background
Prostate cancer is the most common malignancy in men
in the United States [1]. While the mortality of prostate
cancer has been slightly reduced recently, it still contri-
butes to 30,000 deaths annually with the majority from
castration resistant prostate cancer (CRPC) [2]. The
androgen-signaling pathway, mediated mostly through
the androgen receptor (AR), plays a critical role in the
regulation of prostate cancer cell growth and survival
[3,4]. Androgen deprivation is the standard therapy for
advanced prostate cancer [5]. However, within two to
three years after initiating therapy, most patients relapse
with a more aggressive form of prostate cancer, termed
CRPC, for which there is no effective treatment.
The c-Met receptor tyrosine kinase (RTK) was originally
discovered as an oncoprotein and has been implicated in
the proliferation and progression of a wide variety of
human malignancies, including prostate cancer [6-9]. High
c-Met expression is observed in late stages and metastases
of prostate cancer [8,10]. Additionally, an inverse correla-
tion between the expression of AR and c-Met has been
observed in prostate epithelium and prostate cancer cell
lines [8,10]. Recently, we demonstrated that AR sup-
pressed c-Met transcription and that increased c-Met
expression was induced by removal of androgens in pros-
tate cancer cells [11]. These data elucidated a biological
role for AR in c-Met transcription that may directly con-
tribute to the pathogenesis of CRPC. While the current
androgen deprivation therapy represses the expression of
growth promoting genes that are activated by the AR, it
may also attenuate the suppressive role of AR on c-Met
expression and contribute to tumor progression.
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any medium, provided the original work is properly cited.In this study, we directly assessed the inhibition of c-Met
signalling pathway in prostate cancer cell growth and
tumor formation and progression using two c-Met inhibi-
tors, PHA-665752 and PF-2341066. These inhibitors have
shown potency and specificity for inhibiting c-Met activa-
tion in a variety of human tumor cells [12-16]. We first
tested the anti-proliferative effect of these inhibitors on a
variety of human prostate cancer cell lines. We then exam-
ined the effect of PF-2341066 in inhibiting the prolifera-
tion of LNCaP tumors in renal subcapsular mouse models.
Finally, we assessed the effect of co-inhibition of c-Met
and androgen signalling pathways in prostate cancer pro-
gression using PF-2341066 and castration in an orthotopic
xenograft model. Through these in vitro and in vivo
experimental approaches, we explored a future therapeutic
strategy of combining c-Met inhibitors with standard
androgen ablation therapy for advanced prostate cancer.
Methods
Cell culture
Human prostate cancer cell line LAPC4 was maintained
in RPMI phenol-red free (Invitrogen, Carisbad, CA) sup-
plemented with 5% fetal bovine serum (FBS, HyClone,
Denver, CO) [17-19]. Human prostate cancer cell line
CWR22Rv1 was maintained in RPMI (Invitrogen) sup-
p l e m e n t e dw i t h5 %F B Sa n do b t a i n e df r o mt h eA m e r i -
can Tissue Culture Collection (ATCC) (CRL-2505).
Human prostate cancer cell lines LNCaP, LNCaP C4-2,
and LNCaP C4-2B were maintained in T medium (Invi-
trogen) supplemented with 5% FBS [18]. Human pros-
tate cancer cell lines DU-145 and PC-3 were maintained
in DMEM supplemented with 5% FBS and obtained
from ATCC (HTB-81, CRL-1435).
Cell proliferation and colony formation assays
Five hundred cells per well were seeded in triplicate in
96-well plates in suitable media mentioned above. Appro-
priate controls or designated concentrations of PHA-
665752 or PF-2341066 dissolved in DMSO were added to
each well after 4 hours, and cells were then incubated for
up to 8 days. Cell proliferation assays were carried out
using the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) tetrazo-
lium kit (Promega, Madison, WI) as suggested by the
manufacturer. For colony formation assay, 50 cells per well
were plated in quadruplicate in 6-well plates for 24 hr, and
then 5 μM of PHA-665752 or PF-2341066 dissolved in
DMSO was added to each well. Cells were then grown for
10 days then fixed and stained with crystal violet in metha-
nol. Each visible colony (> 50 cells) was manually counted.
C-Met inhibitors
PHA-665752 [(2R)-1-[[5-[(Z)-[5-[[(2,6-Dichlorophenyl)
methyl]sulfony l]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]
methyl]-2,4-dim ethyl-1H-pyrrol-3-yl]carbonyl]-2-
(1-pyrrolidinylmethyl) pyrrolidine] was acquired from
Tocris Bioscience, Missouri 12. PF-2341066 [(R)-3-[1-(2,6-
dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-
pyrazol-4-yl)-pyridin-2-ylamine] was provided by
Dr. James Christensen in Pfizer, La Jolla Laboratories [14].
Western blotting
To prepare the whole-cell lysate, cells were washed with
cold PBS and resuspended in radioimmunoprecipitation
assay (RIPA) buffer, 1% NP40, 0.1% SDS, 50 mM NaF,
0.2 mM Na3VO4,0 . 5m MD T T ,1 5 0m MN a C l ,2m M
EDTA, 10 mM sodium phosphate buffer (pH 7.2). Pro-
tein samples boiled in SDS-sample buffer were resolved
on a 6% SDS-PAGE, transferred onto a nitrocellulose
membrane, and then blotted with a polyclonal anti-c-
Met antibody (Santa Cruz Biotechnology, Santa Cruz,
CA), monoclonal anti-phospho-c-Met antibody (Cell
Signaling Technology, Danvers, MA), or monoclonal
anti-tubulin antibody (Thermo Scientific, Fremont, CA).
Blots were detected using the enhanced chemilumines-
cence kit (Amersham, Arlington Heights, IL).
Animal studies
All animal studies performed in this study conformed to
the Helsinki Declaration and to local legislation. The
research was approved by the ethics committee of the
Administrative Panel on Laboratory Animal Care at
Stanford University. Male nonobese diabetic-severe
combined immunodeficient (NOD-SCID) mice (6 weeks
old) were obtained from Jackson Laboratory (Bar Har-
bor, ME), and maintained and cared in accordance with
the Guide for the Care and Use of Laboratory Animals.
LNCaP C4-2 cells were suspended in unpolymerized
rat tail collagen to make collagen grafts (5 × 10
5 cells
per graft). Two grafts were implanted under the renal
capsule of each male NOD-SCID mouse that was then
subcutaneously implanted with a testosterone pellet (10
mg/mouse) [20,21]. At 1 week post-grafting, one group
of randomly chosen mice was started on daily treatment
with PF-2341066 at 50 mg/kg given in water by oral
gavage for 3 weeks. At 4 weeks post-grafting, these ani-
mals were sacrificed with the control group on water
only. The grafts from the mice on water (n = 8) or PF-
2341066 (n = 10) were harvested, weighed, and fixed for
pathological analyses. Significant differences in graft
weight between the treated versus the control groups
were determined using Student’s t test.
For the orthotopic xenograft mouse model, LNCaP
cells (1 × 10
6) were suspended in 50 μlo fu n p o l y m e r -
ized rat tail collagen and injected into the dorsal pros-
tate of male NOD-SCID mice, supplemented with
testosterone pellets (10 mg/mouse) [22-25]. At five
weeks post-implantation, a subset of mice (n = 4) was
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lyses as a pre-castration group. The remaining mice
were castrated and the testosterone pellets were
removed. At one week post-castration, animals were
either given daily treatment with PF-2341066 at 50 mg/
kg in water (n = 7) or water only as controls (n = 6) by
oral gavage for 3 weeks. Then, the mice were sacrificed
and the prostate and pelvic lymph nodes were harvested
and fixed for pathological analyses.
Immunohistochemistry
Tissues were fixed in 10% neutral buffered formalin,
processed, cut at 4 μm intervals, dewaxed, and hydrated
as described previously [11]. Endogenous peroxidase
activity was blocked with 0.5% hydrogen peroxide and
then incubated with the blocking solution (ImmunoVi-
sion Technology, Springdale, AR). The adjacent sections
were incubated with primary antibody or nonimmune
mouse or rabbit IgG overnight at 4°C (Zymed Corp, So.
San Francisco, CA). The mouse anti-human AR (Santa
Cruz Biotechnology), rabbit anti-human PSA (DAKO,
Carpinteria, CA), or rabbit anti-human Ki67 (Leica
Microsystems, Bannockburn, IL) was used at dilutions
of 1:300, 1:3000, or 1:3000, respectively, in PBS with 1%
goat serum. Following incubation, sections were washed,
incubated with a biotinylated goat anti-rabbit or anti-
mouse antibody (Vector Laboratories, Burlingame, CA)
at a dilution of 1:500, and then incubated with avidin-
biotin complex (Vector Laboratories) at a dilution of
1:500. All sections used for immunohistochemistry were
lightly counterstained with 5% (w/v) Harris hematoxylin.
Stained sections were analyzed using an Olympus BX51
light microscope and DP70 camera with a 20× objective
lens. Quantitative Ki67 index was determined by count-
ing the number of Ki-67-positive cells relative to the
number of total cells in more than five fields of two
representative sections from each sample via light
microscopy.
Results
C-Met inhibitors decrease proliferation of AR negative
prostate cancer cells
PC-3 and DU-145 are two frequently used human pros-
tate cancer cell lines that have shown strong c-Met
expression [7,8,10,26]. We examined the effect of two
small molecule inhibitors for c-Met, PHA-665752 and
PF-2341066, on the growth of PC-3 and DU-145 cells
by MTS assays. As shown in Figures 1A, both PHA-
665752 and PF-2341066 fully inhibited the growth of
PC-3 cells at 2.5 μM, which is consistent with earlier
pharmacokinetic and efficacy studies on other human
cancer cells lines [12-16]. The effect was sustained over
time during the course of the experiments. An almost
identical effect of PHA-665752 was observed on DU-145
cells during the course of the experiments though
PF-2341066 showed a slightly weaker inhibition at
2.5 μM (Fig. 1B). We then assessed the inhibitory effects
of PHA-665752 and PF-2341066 using colony formation
assay. Approximately 50 tumor cells were seeded in
each well in the presence of 5 μM PHA-665752 or PF-
2341066. In both PC-3 and DU-145 cells, there was no
visible colony formation in the presence of either inhibi-
tor after 8 days (Fig. 1C). The above data demonstrated
an inhibitory effect of the two c-Met inhibitors on the
proliferation of prostate cancer cells.
As described previously, PHA-665752 and PF-2341066
were one class of selective, ATP-competitive c-Met inhi-
bitors defined by the indolin-2-one core structure
[12,14]. They inhibit tyrosine phosphorylation of c-Met
to block activation of the receptor for downstream sig-
naling. To directly assess the role of these inhibitors on
c-Met phosphorylation, we cultured PC-3 and DU-145
cells in the presence of 0.5 μM of PHA-665752 or
PF-2341066. After 3 hr treatment, whole cell lysates
were isolated and analyzed by Western blotting. While
similar levels of the c-Met protein appeared in both
inhibitor treated and untreated samples from PC-3 and
DU-145 cells, phosphorylated c-Met protein was not
detected in the samples treated with the inhibitors
(Fig. 1D). The results demonstrated that both PHA-
665752 and PF-2341066 inhibit the phosphorylation of
c-Met in prostate cancer cells.
C-Met inhibitors reduce proliferation of AR positive
prostate cancer cells
AR is still expressed in most CRPC and plays a critical
role during disease progression [3,4,27,28]. To extend
our study to this clinical scenario, we next examined the
effect of the c-Met inhibitors in LNCaP, an AR positive
androgen sensitive prostate cancer line, and LNCaP
C4-2, an androgen-insensitive subline, derived from
LNCaP cells grown in a castrated host [18]. The effect
of c-Met inhibitors on LNCaP and its subline was
assessed in MTS assay. Both PHA-665752 (Fig. 2A) and
PF-2341066 (Fig. 2B) showed a dose dependent inhibi-
tion in the growth of LNCaP and LNCaP C4-2 cells.
Interestingly, C4-2 cells showed a greater response to
PHA-665752 and PF-2341066 mediated inhibition than
LNCaP cells, supporting the previous observation that
androgen insensitive cells have higher expression of
c-Met [7,8,10]. Similar inhibitory effects of PHA-665752
and PF-2341066 on LNCaP and C4-2 cells were also
observed in colony formation assays (Fig. 2C). The
above data demonstrated a suppressive effect of the
c-Met inhibitors on the growth of AR positive prostate
cancer cells.
Next, we further assessed the effect of the c-Met inhibi-
tors on other AR positive prostate cancer cell lines,
Tu et al. BMC Cancer 2010, 10:556
http://www.biomedcentral.com/1471-2407/10/556
Page 3 of 10Figure 1 c-Met inhibitors repressed cell growth and c-Met receptor phosphorylation in PC-3 and DU-145 prostate cancer cells.( A) PC-3
cells were cultured with DMEM supplemented with 5% FBS. The c-Met inhibitor, PHA-665752 or PF-2341066, dissolved in DMSO was added to
the growth media at the indicated concentration. Cells were harvested and analyzed by the MTS assay at indicated time-points. Absorbance at
490 nm was measured in triplicate samples. The data represent the mean ± S.D. of three independent experiments. (B) The similar MTS assays
were carried out in DU-145 cells. (C) Approximately 50 PC-3 or DU-145 cells per well were plated in quadruplicate in 6-well plates for 24 hr, and
then PHA-665752 or PF-2341066 was added to cells. Cells were allowed to grow for 10 days then fixed and stained with crystal violet. (D) PC-3
or DU-145 cells were cultured with 5% FBS-DMEM and were then exposed for 3 hours to DMSO alone, 0.5 μM of PHA-665752, or 0.5 μMo f
PF-2341066 dissolved in DMSO. Whole cell lysates were prepared from the above cells for immunoblotting with c-Met or phosphorylated c-Met
antibody, as well as the b-tubulin antibody as a loading control.
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Page 4 of 10including LAPC4, LNCaP C4-2B, and CWR22Rv1
[17-19]. In MTS assays, all of the above cell lines showed
dose dependent growth inhibition in the presence of
PHA-665752 or PF-2341066 compared to DMSO vehicle
control. Analysis of the relative inhibition rates of PHA-
665752 or PF-2341066 at 2.5 μM on prostate cancer cells
showed an inverse association between drug responsive-
ness and androgen sensitivity status (Fig. 2D). Two AR
negative cell lines, PC-3 and DU-145, were most respon-
sive to the c-Met inhibitors followed by the androgen
insensitive cells, LNCaP C4-2, C4-2B, and CWR22Rv1,
whereas the androgen sensitive LNCaP and LAPC4 cells
Figure 2 c-Met inhibitors suppressed growth of AR positive prostate cancer cells, especially androgen insensitive type.( A) Both LNCaP
and LNCaP C4-2 cells were analyzed in MTS assay in the presence of PHA-665752. The average relative cell proliferation after 8 days as a
percentage of proliferation in the DMSO vehicle control ± SE of triplicate samples was plotted, and the significant difference was observed as
*P < 0.01 (Student’s t test). (B) The effect of PF-2341066 on LNCaP and LNCaP C4-2B cells was tested and analyzed similarly as (A). The significant
difference was shown, *P < 0.01 (Student’s t test). (C) Approximately 50 LNCaP or LNCaP C4-2 cells per well were plated in quadruplicate in
6-well plates for 24 hr, and then 5 μM of PHA-665752 or PF-2341066 was added. Cells were fixed and stained with crystal violet in methanol at
day 10. (D) The relative anti-proliferative effect of PHA-665752 or PF-2341066 at 2.5 μM on different prostate cancer cells was compared.
A significant difference, **P < 0.01 (Student’s t test), between two AR positive cell lines, LNCaP and LAPC4, and other AR negative and androgen
insensitive cells was observed.
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cated that c-Met inhibition had greater anti-proliferative
efficacy as prostate cancer cells became more androgen
resistant.
C-Met inhibitor, PF-2341066, suppresses growth of AR
positive prostate tumors in mice
Next, we assessed the potential of c-Met inhibitor in
tumor formation of AR positive, androgen insensitive
cells using an in vivo mouse model. Specifically, we
tested the efficacy of PF-2341066 since it was more
clinically relevant as an orally bioavailable and water-
soluble drug [14]. The subcapsular renal tumor model
w a sc h o s e ni nt h i ss e to fe x p e r i m e n t sf o ri t sh i g h
implant survival rate and ease in separating tumor from
host tissue for accurate measurements of tumor growth
[11,20,21].
AR positive LNCaP C4-2 cells were grafted under the
kidney capsule of 8 week-old male SCID mice as
reported previously [11,21]. One week after grafting,
mice were divided into groups that received either daily
oral gavage with 50 mg/kg of PF-2341066 (n = 10) or
water only (n = 8) for 3 weeks. At the end of 4 weeks,
mice were sacrificed and tumor grafts were harvested,
weighed, and fixed in formalin for further pathological
analysis. LNCaP C4-2 tumor grafts were observed under
the capsule of kidneys as presented in Figure 3A. Histo-
logic evaluation of the graft tissues showed a mass of
LNCaP C4-2 tumor cells. Tumor cells showed positive
nuclear immunostaining for human AR and cytoplasmic
staining for human PSA, confirming the tumor origin as
LNCaP C4-2 cells. Analysis of LNCaP C4-2 tumor grafts
showed that the weights of tumors in mice treated with
PF-2341066 were significantly less than the ones in
water vehicle controls (Fig. 3B).
To determine if the difference in tumor growth was
associated with an anti-proliferative effect, immunostain-
ing for the proliferation marker Ki67 was performed on
the above graft tumor tissues isolated from either the
control group (left panel, Fig. 3C) or PF-2341066 treated
mice (right panel, Fig. 3C). The relative proliferative
index as a percent of Ki67 positive cells was significantly
reduced in the tissues isolated from mice treated with
PF-2341066 (Fig. 3D). These data demonstrated that the
c-Met inhibitor suppresses the growth of AR positive,
androgen insensitive prostate cancer cells in xenograft
mouse models, implying a potential use of the inhibitor
in repressing the progression of prostate cancer cells.
C-Met inhibitor, PF-2341066, represses prostate cancer
cell growth during the progression of AR positive
prostate tumors in castrated mice
Previous studies have shown that the orthotopic prostate
cancer mouse model can mimic the course of human
Figure 3 c-Met inhibitor decreased proliferation of androgen
receptor positive cells in vivo. LNCaP C4-2 cells were implanted
into the renal capsule of male SCID mice supplemented with
testosterone as described in the “Materials and Methods”. At day 28,
mice were sacrificed and the grafted tumor mass was identified. (A)
Representative tumor tissue stained with hematoxylin and eosin, or
analyzed by immunostaining with human AR or PSA antibody,
respectively. (B) Tumor tissues were harvested and weighed from
mice given water or daily oral gavage of PF-2341066 at 50 mg/kg.
The difference of weight was analyzed by Student’s t test (*P <
0.01). (C) Representative tumor tissue isolated from mice given
water (left) or daily oral gavage of PF-2341066 at 50 mg/kg (right)
and analyzed by immunostaining with Ki67 antibody. (D) Positive
cells with Ki67 antibody were counted in more than 5 different
fields, and the Ki67 index was measured as the number of the
positive Ki67 cells relative to the number of total cells in two
representative sections. There was a difference between the control
and treated mice, *P < 0.01 (Student’s t test).
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this model, AR positive and androgen sensitive LNCaP
cells were implanted into mouse prostates. After tumor
development, mice were castrated. LNCaP cells were
initially inhibited after castration, then regained growth
ability and developed castration resistant disease with
potential for metastasis. Thus, we used this model to
directly test whether co-targeting androgen and c-Met
signaling pathways could effectively inhibit tumor cell
growth.
Approximately 1 × 10
6 LNCaP cells were orthotopi-
cally implanted into the dorsal prostate of each 8 week-
old male SCID mouse that was then supplemented with
testosterone. At five weeks post-implantation, a subset
of mice (n = 4) as a pre-castration group was sacrificed
to harvest the prostates for evidence of tumor formation
after orthotopic implantation and to determine a base-
line cancer cell proliferation rate. Hematoxylin and
eosin staining showed clusters of large cells with nuclear
atypia adjacent to normal mouse prostate glands in 3 of
4 mice (Fig. 4A). Positive immunostaining of serial sec-
tions for human AR (middle, Fig. 4A) and PSA (right,
Fig. 4A) demonstrated that LNCaP tumors formed in
the mouse prostate after orthotopic implantation.
To study the progression of the tumors, the remaining
mice were castrated. At one-week post-castration, one
subset of castrated mice (n = 7) was given daily oral
gavage with 50 mg/kg of PF-2341066 in water for 3
weeks. Another group of mice (n = 6) was given water
only for 3 weeks as controls. Mice were sacrificed and
carefully examined at the end of the fourth week of cas-
tration. In the control group, LNCaP tumors appeared
in 4 of 6 mice. Large tumor cells with nuclear atypia
were clearly observed in the samples stained with hema-
toxylin and eosin (left, Fig. 4B). Identity of LNCaP cells
was further confirmed by positive immunostaining for
human AR (middle, Fig. 4B) and PSA (right, Fig. 4B). In
addition, a pelvic lymph node metastasis of LNCaP cells
was identified by immunostaining in one of the mice
without treatment. In PF-2341066 treated mice, 4 of 7
mice showed LNCaP tumors in prostate tissues but no
mouse had lymph node lesions.
To determine the effect of PF-2341066 on the growth
of LNCaP cells in castrated mice, we carried out immu-
nostaining of Ki67 on prostate tissues from the above
different groups of mice. The Ki67 index from pre-
castration mice was similar to the control mice treated
with water, indicating development of castration resis-
tant growth. The prostate tumor samples isolated from
PF-2341066 treated mice showed a marked reduction in
Ki67 staining (right, Fig. 4C) compared to the ones from
control mice (left, Fig. 4C). The proliferative index as a
percent of Ki67 positive cells was significantly lower
from PF-2341066 treated mice than in control mice
treated with water and pre-castration mice (Fig. 4D).
Taken together, the above data suggested that the
administration of a c-Met inhibitor after castration
reduces subsequent proliferation of castration resistant
prostate cancer cells.
Discussion
Since the pioneering work in 1941 by Charles Huggins
and Clarence Hodges that castration could be effective
for metastatic prostate cancer, androgen deprivation
therapy has been widely used to treat advanced prostate
cancer [29]. Although different medications have been
developed and applied to patients for the purpose of
reducing the level of androgens or competitively repres-
sing AR function, the fundamental premise of this ther-
apy has remained almost unchanged. Within 2-3 years
of the therapies, most patients develop more aggressive
disease, CRPC. Therefore, it is urgent to develop more
effective therapeutic strategies for advanced prostate
cancer to prevent the development of CRPC.
Recent work including data from our lab has created a
p a r a d i g ms h i f tb ys h o w i n gar o l eo fA Ri nt r a n s c r i p -
tional repression [11,30]. Our previous data demon-
strated that AR suppressed c-Met transcription in
LNCaP prostate cancer cells and castration of SCID
mice bearing LNCaP xenografts induced c-Met expres-
sion in the tumors [11]. Knockdown of c-Met using spe-
cific c-Met siRNA inhibited the induction of c-Met
expression by androgen depletion and repressed prostate
cancer cell growth [31]. Decreasing c-met expression
using ribozyme technology resulted in reduced prostate
cancer cell proliferation and orthotopic tumor formation
using PC-3 cells [26]. The c-Met receptor tyrosine
kinase had been shown to be involved in tumor prolif-
eration and progression and overexpression of c-Met
had been associated with advanced prostate cancer
[6-10]. These data suggested that the therapeutic strat-
egy of inhibiting the activation of both HGF/c-Met and
AR signaling pathways should be considered in the
treatment of advanced prostate cancer.
In this study, we used two recently developed small
molecule inhibitors for c-Met receptor, PHA-665752
and PF-2341066, to test the inhibition of c-Met activa-
tion in the growth and progression of prostate cancer
cells. First, we evaluated the efficacy of two small mole-
cule inhibitors for c-Met, PHA-665752 and PF-2341066,
in a variety of prostate cancer cell lines. We observed
significant inhibitory effects of these inhibitors on all the
cell lines used here. In addition, we also confirmed that
these small molecule inhibitors block phosphorylation of
c-Met to inhibit its activation and downstream signalling
[12,14]. In this study, we compared the repressive effect
of these small molecule inhibitors in androgen sensitive
and insensitive cell lines. Interestingly, we observed a
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Page 7 of 10Figure 4 c-Met inhibitor combined with castration reduced proliferation of castration resistant prostate cancer cells in vivo.L N C a P
cells were orthotopically implanted into the prostates of male SCID mice supplemented with testosterone (see “Materials and Methods”). (A)
Prostate tissue isolated from a representative non-castrated 11 week-old male SCID mouse and analyzed with hematoxylin and eosin staining
and immunohistochemistry with the human AR antibody or PSA antibody. (B) Prostate tissue stained with hematoxylin and eosin, human AR
antibody, and PSA antibody that was isolated from a representative 15 week-old male SCID mouse that had been castrated at 11 weeks-old. (C)
Representative prostate tissue analyzed with Ki67 antibody that was isolated from castrated animals that were given either water (left) or
PF-2341066 at 50 mg/kg (right) for 4 weeks post-castration. (D) Ki67 index was measured in pre-castration, control castrated mice on water, and
castrated mice treated with PF-2341066. There was a significant difference between control and treated mice, *P < 0.01 (Student’s t test).
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gen-insensitive cells than androgen-sensitive cells. This
correlated with previous publications showing that
androgen-insensitive cells possessed higher cellular
levels of c-Met [7,8,10,32,33]. As we have shown pre-
viously, although these androgen-insensitive cells
remained AR positive, the repressive effect of AR on c-
Met expression in these cells appeared diminished or
reduced [11]. Multiple lines of evidence have suggested
that action and regulation mediated by AR may be dif-
ferent in androgen-sensitive and insensitive status
[34,35]. Therefore, further investigation of the regulatory
mechanisms of AR in these different stages would be
extremely important to understand the molecular basis
of the switch between androgen-sensitive and insensitive
during prostate cancer progression.
To examine whether co-targeting androgen and c-Met
signaling pathways could effectively impede the progres-
sion of prostate cancer, we initially demonstrated the
feasibility and effectiveness of the c-Met inhibitor on
repression of the proliferation of prostate cancer cells in
a xenograft mouse model using an orally bioavailable
c-Met small molecule inhibitor, PF-2341066 [11,20,21].
We observed a significant 48% reduction in gross tumor
weight and 45% reduction in proliferation when com-
paring PF-2341066 treated mice to control mice. Using
an AR positive, androgen insensitive prostate cancer cell
line, LNCaP C4-2, we showed for the first time that
PF-2341066 inhibited the growth of AR positive prostate
tumor xenografts in vivo.
Next, we tested targeted therapy to c-Met with castra-
tion in an orthotopic mouse model to determine the effec-
tiveness of combination therapy in inhibiting prostate
cancer progression. Intraprostatic injection of LNCaP cells
into SCID mice had been shown to lead to tumor forma-
tion within one month in this mouse model [36-38]. Sub-
sequent castration of these mice initially delayed tumor
growth but LNCaP cells eventually regained growth ability
and developed androgen-insensitive tumors [22-25]. We
chose a dosing schedule of three weeks based upon a prior
study showing in vivo effectiveness of PF-2341066 on
prostate cancer cells [14]. Intriguingly, we observed a sig-
nificant 85% reduction in proliferation when comparing
PF-2341066 treated castrated mice versus control
castrated mice. This elucidated that targeting of c-Met sig-
nalling as an adjunct to standard androgen deprivation
therapy may reduce the development of castration resis-
tant tumors. In addition to PHA-665752 and PF-2341066
tested in our study, other small molecule c-Met receptor
tyrosine kinase inhibitors have also been developed and
showed an inhibitory effect in non-prostate and prostate
cancer cell lines [39,40]. In particular, Dai et al. reported
in PC-3 cells that their c-Met inhibitor had anti-motogenic
and anti-proliferative effects depending upon the drug
concentration. This was similar to the previously pub-
lished data on PHA-665752 and PF-2341066 [12,14]
Taken together, these most recent findings and the results
from this study provided important information on the
potential of selective molecular therapy for advanced pros-
tate cancers.
Conclusions
Effective treatment for advanced prostate cancer has an
urgent need in prostate cancer research. In this study,
we demonstrated that two newly developed c-Met inhi-
bitors, PHA-665752 and PF-2341066, repress the growth
of a variety of prostate cancer cell lines. We observed an
inhibitory effect of PF-2341066 on the proliferation of
AR positive tumors in renal subcapsular mouse models.
Moreover, using an orthotopic xenograft model, we
showed that co-inhibition of c-Met and androgen signal-
ling pathways using PF-2341066 and castration signifi-
cantly reduced the proliferation of prostate cancer cells
during progression after castration. Data from this study
shed fresh light on possible future treatment by co-
targeting c-Met and androgen signalling pathways in
advanced prostate cancers.
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